Stockscreener 앱 받기
6.34
2.76%
0.17
시간 외 거래:
6.34
전일 마감가:
$6.17
열려 있는:
$6.23
하루 거래량:
604.52K
Relative Volume:
0.57
시가총액:
$657.49M
수익:
순이익/손실:
$-112.39M
주가수익비율:
-3.5955
EPS:
-1.7633
순현금흐름:
$-91.64M
1주 성능:
-2.54%
1개월 성능:
-8.38%
6개월 성능:
-10.58%
1년 성능:
-0.16%
1일 변동 폭
$6.17
$6.415
1주일 범위
$6.085
$6.70
52주 변동 폭
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
명칭
Aura Biosciences Inc
전화
(617)500-8864
주소
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.34 | 657.49M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-26 | 재개 | Evercore ISI | Outperform |
| 2025-05-28 | 재개 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | H.C. Wainwright | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2022-07-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Aura Biosciences Inc 주식(AURA)의 최신 뉴스
Forbion Entities Reveal 5.1% Stake in Aura Biosciences via SEC Filing - Kalkine Media
Three entities report a passive stake above 5% in Aura Biosciences (AURA). - Stock Titan
Biomea Fusion Announces Proposed Public Offering of Securities - Yahoo Finance
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences to Participate in Upcoming Investor Conference - GlobeNewswire
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16 - Stock Titan
Aura Biosciences (AURA) boosts finance chief with new stock grants - Stock Titan
COO at Aura Biosciences (AURA) lands new option and RSU package - Stock Titan
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives - quiverquant.com
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura (AURA) Results at a Glance: EPS Misses Its Estimate under the Current Snapshot; Market Move: Shares Move 0.39% Higher on the DayGuidance Revision Trend - vinanet.vn
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Long Focus Capital Management Expands Stake in Aura Biosciences Inc (AURA) With Strategic Add - GuruFocus
Aura (AURA) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison for the Current Session; Price Move - vinanet.vn
Aura Biosciences Extends Bel-sar Data With Long-Term Follow-Up Study - TipRanks
AURA Q1 2026 Earnings: Wider Net Loss of $0.50 Per Share Weighs on SharesEstimate Revision Count - vinanet.vn
AURA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Commercial Pipeline CostsRevenue Warning Signal - vinanet.vn
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - MarketBeat
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - theglobeandmail.com
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Canada
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - tradingview.com
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Canada
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - TipRanks
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences Inc (AURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aura Biosciences Inc 주식 (AURA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks |
Jun 16 '26 |
Sale |
6.42 |
12,824 |
82,330 |
265,354 |
| Matrix Capital Management Comp | 10% Owner |
May 07 '26 |
Sale |
5.64 |
6,922,870 |
39,044,987 |
0 |
| Kilroy Conor | Officer |
Apr 16 '26 |
Proposed Sale |
7.02 |
11,738 |
82,402 |
0 |
| Kilroy Conor | See Remarks |
Apr 16 '26 |
Sale |
7.02 |
11,738 |
82,401 |
217,835 |
| Kilroy Conor | Officer |
Feb 17 '26 |
Proposed Sale |
5.05 |
12,079 |
61,037 |
0 |
| Plavsic Mark | Officer |
Feb 17 '26 |
Proposed Sale |
5.05 |
15,890 |
80,271 |
0 |
| Hopkins Janet Jill | Officer |
Feb 17 '26 |
Proposed Sale |
5.06 |
20,401 |
103,231 |
0 |
| Elazzouzi Amy | Officer |
Feb 17 '26 |
Proposed Sale |
5.06 |
8,549 |
43,261 |
0 |
| de los Pinos Elisabet | Officer |
Feb 17 '26 |
Proposed Sale |
5.06 |
47,648 |
241,063 |
0 |
| Kilroy Conor | See Remarks |
Feb 17 '26 |
Sale |
5.05 |
12,079 |
60,999 |
167,234 |
7.71%
1.20%
자본화:
|
볼륨(24시간):